Markets
Opus Genetics COO Sells $13,653 in Stock: What Insider Transactions Signal for OPGN Investors
Opus Genetics COO Joseph Schachle has offloaded $13,653 worth of common stock, putting insider activity at this clinical-stage gene therapy company under the microscope. Here's what the transaction reveals — and what traders should watch next.